prrlsin.cppt.pgk-gfp.wpre Search Results


prrlsin cppt pgk gfp wpre lentiviral shuttle plasmid  (Addgene inc)
95
Addgene inc prrlsin cppt pgk gfp wpre lentiviral shuttle plasmid
Figure 1 Cell encapsulation device for long-term subcutaneous therapeutic antibody delivery. (A) Schematic representation of ECT for passive immunization. Allogeneic cells are genetically engineered using <t>lentiviral</t> vectors to produce a therapeutic antibody. The modified cells are confined in a macroencapsulation ‘flat sheet’ device and implanted in the subcutaneous tissue for in vivo antibody secretion. (B) Macroscopic view of the encapsulation device, composed of a transparent frame supporting polymer permeable membranes and reinforced with an outer polyester mesh. (C) Dense neovascularization develops around a device containing antibody-secreting C2C12 myoblasts, 8 months after implantation in the mouse subcutaneous tissue. (D and E) Representative photomicrographs showing encapsulated antibody-secreting C2C12 myoblasts surviving at high density within the flat sheet device 39 weeks after implantation. (E) Higher magnification: note that the cells produce a collagen-rich matrix stained in blue with Masson’s trichrome protocol. Asterisk: polypropylene porous membrane. Scale bars = 750 mm (B and C), 100 mm (D), 50 mm (E).
Prrlsin Cppt Pgk Gfp Wpre Lentiviral Shuttle Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prrlsin cppt pgk gfp wpre lentiviral shuttle plasmid/product/Addgene inc
Average 95 stars, based on 1 article reviews
prrlsin cppt pgk gfp wpre lentiviral shuttle plasmid - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Figure 1 Cell encapsulation device for long-term subcutaneous therapeutic antibody delivery. (A) Schematic representation of ECT for passive immunization. Allogeneic cells are genetically engineered using lentiviral vectors to produce a therapeutic antibody. The modified cells are confined in a macroencapsulation ‘flat sheet’ device and implanted in the subcutaneous tissue for in vivo antibody secretion. (B) Macroscopic view of the encapsulation device, composed of a transparent frame supporting polymer permeable membranes and reinforced with an outer polyester mesh. (C) Dense neovascularization develops around a device containing antibody-secreting C2C12 myoblasts, 8 months after implantation in the mouse subcutaneous tissue. (D and E) Representative photomicrographs showing encapsulated antibody-secreting C2C12 myoblasts surviving at high density within the flat sheet device 39 weeks after implantation. (E) Higher magnification: note that the cells produce a collagen-rich matrix stained in blue with Masson’s trichrome protocol. Asterisk: polypropylene porous membrane. Scale bars = 750 mm (B and C), 100 mm (D), 50 mm (E).

Journal: Brain : a journal of neurology

Article Title: A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.

doi: 10.1093/brain/aww036

Figure Lengend Snippet: Figure 1 Cell encapsulation device for long-term subcutaneous therapeutic antibody delivery. (A) Schematic representation of ECT for passive immunization. Allogeneic cells are genetically engineered using lentiviral vectors to produce a therapeutic antibody. The modified cells are confined in a macroencapsulation ‘flat sheet’ device and implanted in the subcutaneous tissue for in vivo antibody secretion. (B) Macroscopic view of the encapsulation device, composed of a transparent frame supporting polymer permeable membranes and reinforced with an outer polyester mesh. (C) Dense neovascularization develops around a device containing antibody-secreting C2C12 myoblasts, 8 months after implantation in the mouse subcutaneous tissue. (D and E) Representative photomicrographs showing encapsulated antibody-secreting C2C12 myoblasts surviving at high density within the flat sheet device 39 weeks after implantation. (E) Higher magnification: note that the cells produce a collagen-rich matrix stained in blue with Masson’s trichrome protocol. Asterisk: polypropylene porous membrane. Scale bars = 750 mm (B and C), 100 mm (D), 50 mm (E).

Article Snippet: Briefly, cDNAs encoding either the mAb-11 IgG2a light chain or heavy chain were subcloned into the pRRLSIN.cPPT.PGK-GFP.WPRE lentiviral shuttle plasmid (Addgene plasmid #12252).

Techniques: Encapsulation, In Vivo, Polymer, Staining, Membrane